ArticleBMC infectious diseases2026
Trajectories and determinants of respiratory syncytial virus prefusion F-specific IgG in older adults.
Article in BMC infectious diseases, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
Abstract
backgroundRespiratory syncytial virus (RSV) causes substantial morbidity in older adults. However, population-level longitudinal patterns and variability of naturally acquired antibody responses remain insufficiently quantified. We aimed to quantify population-level trajectories and variance components of RSV prefusion F (preF)-specific IgG in older adults.
methodsWe conducted a prospective cohort study of 132 adults aged ≥60 years using residual serum samples, with repeated measurements over one year (666 observations). RSV preF-specific IgG levels were measured by enzyme-linked immunosorbent assay. Population-level trends were estimated using a linear mixed-effects model with a random intercept, adjusting for key covariates. Exploratory analyses were summarized descriptively to characterize variability.
resultsAt the population level, antibody levels showed no significant temporal change (β = 0.004, SE = 0.003; p = 0.152). Between- and within-individual variability were comparable (SD ≈ 0.247 vs 0.248). Individual slopes were centered near zero (median ≈ 0) with a wide, approximately symmetric distribution. A subset (~31%) exhibited higher variability. No chronic condition was associated with antibody levels after correction for multiple comparisons.
conclusionsRSV preF-specific IgG levels in older adults were stable at the population level over one year, with substantial within- and between-individual variability. These findings reflect population-average trends and variance components estimated from a random-intercept model and should not be interpreted as evidence of individual-level trajectories or underlying biological mechanisms. CLINICAL TRIAL NUMBER: Not applicable.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.